Gufic BioSciences Share Price Today | Stock Price & Gufic BioSciences Share Screener
As of October 5, 2026, the live Gufic BioSciences share price (NSE: GUFICBIO) is ₹419.70 on NSE and ₹420.55 on BSE, up 0.31% from the previous close, with shares trading between ₹410.55 and ₹425.20 in today's trading session, and a 52-week range of ₹273.50–₹448.00. Check GUFICBIO 52-week high low for the annual price range and momentum. Use the Gufic BioSciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gufic BioSciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹261 and net income of ₹22, with EBITDA of ₹47, an operating margin of 18.0% and a profit margin of 8.4%.
Gufic BioSciences Share Price Chart
Track the current stock price of Gufic BioSciences with an interactive chart. Analyse GUFICBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gufic BioSciences stock quote in one place.
The quote of ₹419.70 sits between the 52-week low of ₹273.50 and the 52-week high of ₹448.00, and the latest session moved 0.31% from the previous close.
Gufic BioSciences Company Profile - Fundamental Screener
Screen Gufic BioSciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GUFICBIO shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE742B01025.
Company Details
Classification
Identifiers and Leadership
Gufic BioSciences Balance Sheet Screener
Screen GUFICBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹1,342, up from ₹1,169 in 2025.
Latest statistics put total assets at ₹1,342 and shareholder funds at ₹665, with a leverage ratio of 0.59.
| Item | 2026 | 2025 | 2024 |
|---|---|---|---|
Assets |
|||
| Total Assets | 1,342 | 1,169 | 1,093 |
| Current Assets | 802 | 625 | 601 |
| Fixed Assets | 491 | 506 | 159 |
Liabilities |
|||
| Total Liabilities | 0 | 0 | 0 |
| Current Liabilities | 160 | 181 | 188 |
| Non-Current Liabilities | 0 | 0 | 0 |
Shareholders' Equity |
|||
| Total Equity | 665 | 601 | 533 |
| Share Capital | 10 | 10 | 10 |
| Reserves & Surplus | 655 | 591 | 523 |
Gufic BioSciences Income Statement Screener - Profit & Revenue Analysis
Screen Gufic BioSciences income statement and profit fundamentals. Analyze GUFICBIO quarterly results. Gufic BioSciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹261 and net profit was ₹22, equal to earnings per unit of ₹2.22, at an operating margin of 18%.
In that period expenses were ₹214, interest cost ₹9 and tax ₹8. The next period listed, 2026-Mar, shows revenue of ₹251 and net profit of ₹22.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 261 | 251 | 232 | 239 | 225 | 205 | 210 | 204 | 204 | 196 | 202 | 215 | 196 |
| Expenses | 214 | 205 | 198 | 199 | 190 | 179 | 174 | 166 | 167 | 161 | 165 | 176 | 159 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 47 | 46 | 34 | 40 | 34 | 27 | 36 | 39 | 37 | 35 | 37 | 40 | 36 |
| Operating Profit % | 18.00% | 19.00% | 14.00% | 16.00% | 15.00% | 13.00% | 16.00% | 19.00% | 18.00% | 18.00% | 18.00% | 18.00% | 18.00% |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 8 | 5 | 4 | 4 | 4 | 4 | 4 | 4 |
| Interest | 9 | 9 | 8 | 10 | 9 | 8 | 5 | 5 | 5 | 4 | 3 | 5 | 4 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 30 | 29 | 18 | 23 | 17 | 11 | 26 | 29 | 28 | 27 | 30 | 31 | 28 |
| Tax | 8 | 7 | 5 | 6 | 4 | 3 | 7 | 8 | 7 | 7 | 7 | 8 | 7 |
| Net Profit | 22 | 22 | 12 | 17 | 13 | 8 | 19 | 22 | 21 | 20 | 22 | 23 | 21 |
| EPS | 2.22 | 2.18 | 1.24 | 1.68 | 1.30 | 0.77 | 1.93 | 2.17 | 2.08 | 2.00 | 2.23 | 2.39 | 2.13 |
Gufic BioSciences Cash Flow Screener - Liquidity Fundamentals
Screen GUFICBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹45, and net cash flow was an inflow of ₹47.
Over the same period, investing activities used ₹31 and financing activities provided ₹32.
| Item | 2026-March | 2025-March | 2024-March |
|---|---|---|---|
Cash from Operations and Investing | |||
| Operating Activities | 45 | 123 | -8 |
| Investing Activities | -31 | -71 | -102 |
Financing and Net Cash | |||
| Financing Activities | 32 | -37 | 82 |
| Net Cash Flow | 47 | 15 | -28 |
Gufic BioSciences Shareholding Pattern Screener
See Gufic BioSciences shareholding pattern with promoter, FII, and DII holdings. Check Gufic BioSciences promoter holding and ownership changes for GUFICBIO on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 72.50%, foreign institutions 0.42%, domestic institutions 3.83% and the public 13.93%, spread across 29,223 shareholders.
The shareholder count was 29,223 in 2026-Mar, compared with 29,753 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 72.50% | 72.50% | 72.51% | 72.51% | 72.50% | 72.50% | 72.51% | 72.51% |
Institutional Investors | ||||||||
| FII Holding | 0.42% | 0.46% | 0.31% | 0.32% | 0.34% | 0.44% | 0.12% | 0.23% |
| DII Holding | 3.83% | 3.68% | 3.39% | 3.38% | 3.65% | 3.74% | 2.20% | 2.39% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.93% | 14.00% | 15.15% | 15.10% | 14.45% | 14.13% | 16.72% | 16.36% |
| Other Holding | 9.31% | 9.36% | 8.64% | 8.70% | 9.06% | 9.19% | 8.45% | 8.52% |
| Shareholder Count | 29,223 | 29,753 | 31,844 | 31,876 | 31,420 | 30,362 | 34,695 | 32,250 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gufic BioSciences. Gufic BioSciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.10 per unit for 2026-March, a yield of 0.02%, compared with ₹0.10 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.10, ₹0.10 and ₹0.10 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.10 | 0.02% |
| 2025-March | ₹0.10 | 0.04% |
| 2024-March | ₹0.10 | 0.03% |
| 2023-March | ₹0.10 | 0.04% |
| 2022-March | ₹0.10 | 0.05% |
| 2021-March | ₹0.10 | 0.04% |
| 2020-March | ₹0.05 | 0.04% |
| 2019-March | ₹0.05 | 0.10% |
| 2018-March | ₹0.05 | 0.07% |
| 2017-March | ₹0.05 | 0.05% |
Gufic BioSciences Stock Index Membership - Nifty & Sensex
See which indices include Gufic BioSciences stock. Check GUFICBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 3 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Gufic BioSciences Market Events Screener - Corporate Actions
Get Gufic BioSciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gufic BioSciences stock events that may affect GUFICBIO share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 4, 2026, with a record date of September 4, 2026.
It is followed by Dividend dated August 28, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-04 | 2026-09-04 | Annual General Meeting | NA | 9.05% |
| 2026-08-28 | 2026-08-28 | Dividend | ₹ 0.10 /share | 26.48% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 2.10% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 12.89% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 1.49% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -0.69% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | -3.20% |
| 2025-09-22 | 2025-09-22 | Dividend | ₹ 0.10 /share | -5.49% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -2.72% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 2.75% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -4.73% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.61% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | -0.95% |
| 2024-09-17 | 2024-09-19 | Dividend | ₹ 0.10 /share | 27.37% |
| 2023-09-29 | 2023-09-29 | Annual General Meeting | NA | -7.11% |
Gufic BioSciences Competitors Screener - Peer Stocks Comparison
Screen GUFICBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Gufic BioSciences Company Announcements - News & Reports Screener
Screen GUFICBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 1, 2026 and October 1, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-10-01 | Closure of Trading Window | - |
| 2026-10-01 | Intimation Of Environmental Social And Governance (ESG) Rating | - |
| 2026-09-26 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-08 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-09-07 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-04 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-02 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Promotion And Change In Designation Of Senior Management Personnel | - |
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-08-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-08-14 | Results - Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026 | - |
| 2026-08-14 | Board Meeting Outcome for Meeting Held On Friday August 14 2026 | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-12 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-08-12 | Reg. 34 (1) Annual Report. | - |
| 2026-08-12 | Intimation Of Record Date For Final Dividend And 42Nd Annual General Meeting | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹419.70, within a 52-week range of ₹273.50 to ₹448.00. The P/E ratio is 58.98 and the P/B ratio is 6.51, with earnings per unit of ₹6.40. Market capitalisation stands at ₹4,195.82 Cr and the dividend yield is 0.02%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 3 balance sheet periods, 13 income statement periods, 3 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.